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accelerate the age-related RAA stiffness. The mechanism is probably
associated with the up-regulated level of RAGE in IRSA media,
while the AGEs in serum or IRSA media may be involved in the late
stage.GW26-e4656
Polymorphism of RBP4 Locus Is Associated with 5-Year Survival in acute
coronary syndrome after coronary revascularization
Ke Wan, Zhi Zeng
West China Hospital, Sichuan University
OBJECTIVES The rs7094671 was single nucleotide polymorphism of
RBP4 locus that was associated with prevalence of coronary artery
disease. No data concerning their association with long term prog-
nosis after myocardial infarction is available. The aim of our study was
to investigate the association of the RBP4 locus with 5-year overall
mortality in patients with acute coronary syndrome after coronary
revascularization.
METHODS Cohort study included 292 patients with acute coronary
syndrome treated with primary PCI, followed for up to 5 years. Gen-
otyping was performed with high resolution melting (HRM) analysis.
The analyzed end-point was total 5-year mortality.
RESULTS The baseline characteristics were well-balanced between
carriers (AA, n ¼ 19; AG, n ¼ 73) and GG (n ¼ 200) of the RBP4
variant. During the follow-up period (52.4511.98months), the pri-
mary endpoint occurred more frequently in carriers of A allele than
in non-carriers of A allele (24.8% versus 9.3%; hazard ratio [HR] ¼
2.656; 95% conﬁdence interval [CI] ¼ 1.642–4.295; P ¼ 0.000);
Kaplan–Meier estimation of the primary outcome measure (death of
any cause) during the follow-up period. (AA groups versus GG
groups: adjusted HR ¼ 6.321, 95% CI 2.081–19.205, P ¼ 0.001), GA
groups versus GG groups: adjusted HR ¼ 1.303, 95% CI ¼ 0.478–
3.548, P ¼ 0.605).
CONCLUSIONS The RBP4 locus is associated with 5-year mortality in
high-risk patients with acute coronary syndrome.GW26-e4667
Effect of Oxidatively Modiﬁed Low-Density Lipoprotein on
Osteodifferentiation of Mesenchymal Stem Cells Co-cultured with
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OBJECTIVES Increasing evidences revealed that bone marrow-
derived mesenchymal stem cells (BM-MSCs) played important role in
wound healing and vascular remodeling in vivo. However, the
mechanism in the development of atherosclerosis and vessel calcify
remains unclear. The aim of this study was to investigate the effect
of oxidatively modiﬁed low-density lipoprotein (ox-LDL) on osteo-
diferenliation of BM-MSCs co-cultured with smooth muscle cells
with or without osteogenic inductor, and further to explore the
mechanism of BM-MSCs participating in atherosclerosis and vessel
calcify.
METHODS BM-MSCs and vascular smooth muscle cells (VSMCs) were
prepared from Sprague-Dawley rats and co-cultured in a transwell
coculture system, which allowed the diffusion of secreted factors but
prevented cell contact. Thecombined group (both osteogenic inductor
and ox-LDL), ox-LDL group, osteogenic inductor group and control
group were allocated according to factorial design method. The effect
of ox-LDL on the osteogenic potential was determined by cell
morphology, real-time PCR, immunoﬂuorescent staining, alkaline
phosphatase (AKP) activity and osteopontin (OPN) synthesis.
RESULTS 1. All groups expressed OPN mRNA and AKP and but the
OPN mRNA and AKP expression levels of combined group were
the highest after 7 days and 10 days of cell culture, moreover, there
was positive interaction between osteogenic inductor and ox-LDL
(P <0.01).
2. The result of immunity histochemistry also showed that OPN and
AKP expression levels in combined group were the highest after 14
days of cell culture.
CONCLUSIONS Ox-LDL can promote osteogenic inductor-mediated
osteodifferentiation of BM-MSCs co-cultured with smooth muscle
cells.GW26-e4724
The role of mAKAPb in the process of cardiomyocyte hypertrophy induced
by angiotensin II
Huixin Guo, Baoxin Liu, Yidong Wei
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OBJECTIVES Angiotensin II (AngII) is the central product of the
reninangiotensin system (RAS) and this octapeptide contributes to
the pathophysiology of cardiac hypertrophy and remodeling.
mAKAPb is an Akinase anchoring protein (AKAP) that has the func-
tion of binding to the regulatory subunit of protein kinase A (PKA)
and conﬁning the holoenzyme to discrete locations within the cell.
In this study, we aimed to investigate the role of mAKAPb in AngII
induced cardiomyocyte hypertrophy and the possible mechanisms
involved.
METHODS Cultured cardiomyocytes from neonatal rats were treated
with AngII. Subsequently, the morphology of the cardiomyocytes was
observed and the expression of mAKAPb and cardiomyocyte hyper-
trophic markers was measured. mAKAPb–shRNA was constructed for
RNA interference; the expression of mAKAPb and hypertrophic
markers, the cell surface area and the [3H] Leucine incorporation rate
in the AngII–treated rat cardiomyocytes were detected following RNA
interference. Simultaneously, changes in the expression levels of
phosphorylated extracellular signal–regulated kinase (p-ERK)2 in the
cardiomyocytes were assessed.
RESULTS The cell size of the AngII - treated cardiaomyocytes was
signiﬁcantly larger than that of the untreated cardiomyocytes. The
expression of hypertrophic markers and p-ERK2, the cell surface area
and the [3H] Leucine incorporation rate were all signiﬁcantly
increased in the AngII - treated cells. However, the expression of
mAKAPb remained unaltered in this process. RNA interference
simultaneously inhibited the protein expression of mAKAPb and
p–ERK2, and the hypertrophy of the cardiomyocytes induced by AngII
was attenuated.
CONCLUSIONS AngII induces hypertrophy in cardiomyocytes and
mAKAPb is possibly involved in this process. The effects of mAKAPb
on AngII–induced cardiomyocyte hypertrophy may be associated with
p–ERK2 expression.GW26-e4732
The Effect Of Catecholamine Release-Inhibitory Peptide Catestatin On
Heart Rate And Blood Pressure Of Hypertension
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OBJECTIVES The catecholamine release-inhibitory peptide cate-
statin is an endogenous nicotinic cholinergic antagonist that can
inhibit secretion of catecholamine from chromafﬁn cells and
adrenergic neurons. Therefore it can inhibit sympathetic nerve ac-
tivity. Previous studies have shown that catestatin have a close
relationship with the occurrence and development of hypertension
and that catestatin is diminished in established hypertension.
This study focus on the effect of catestatin on heart rate and
blood pressure of hypertension by supplementing spontaneously
hypertensive rats (spontaneously hypertensive rats, SHR) with
catestatin.
METHODS We used SHR as a hypertensive model and matched it
with the homologous normotensive rats (wistar-Kyoto, WKY) as
normal control group. Blood pressure and heart rate were obtained
from the measurement tail-cuff blood pressure. First, we observed
the difference of blood pressure and heart rate between SHR and
WKY at the age of 6, 12 and 16 weeks. Second, twelve-week-old SHR
were treated with 1mg catestatin via the tail vein injection. Thirty
minutes after injection, heart rate and blood pressure were
measured to observe its short-term effects on blood pressure and
heart rate. Furthermore, we also treated twelve-week-old SHR with
catestatin for 5 weeks (tail vein injection for three times a week,
each 1mg) to observe its long-term effects on blood pressure and
heart rate. Each group has 5 rats.
RESULTS First, the blood pressure and heart rate of SHR were
signiﬁcantly higher than that of WKY at corresponding ages. SHR VS
WKY, six-week-old: heart rate (41828 VS 36624 (beats/min),
P<0.05), blood pressure (1489/1086 VS 11811/859mmHg,
P<0.05); twelve-week-old: heart rate (39730 VS 32625 (beats/min),
P<0.05); blood pressure (19315/15512 VS 1237/9110 mmHg,
